20.500.12556/DKUM-92301 Upravljanje tveganj in zagotavljanje neprekinjenega poslovanja pri dobavi inovativnih zdravil magistrsko delo Ensuring an uninterrupted supply of innovative medicines through the implementation of business continuity and holistic risk management systems Magistrsko delo obravnava problematiko upravljanja tveganj in zagotavljanja neprekinjenega poslovanja pri dobavi inovativnih zdravil. Neprekinjena dobava teh zdravil je ključnega pomena, saj neposredno vpliva na življenje in zdravje pacientov. Farmacevtska podjetja se soočajo z različnimi izzivi, kot so globalne pandemije, politični konflikti, makroekonomska nestabilnost in ekstremni vremenski pojavi, kar zahteva robustne sisteme za obvladovanje tveganj. V nalogi je predstavljen proces strateškega upravljanja tveganj v skladu z ISO 31000 in vzpostavitev sistema neprekinjenega poslovanja v skladu z ISO 22301 v enem izmed vodilnih farmacevtskih podjetij. Preučene so ključne razlike in izboljšave, ki so jih prinesli ti sistemi, zlasti v kontekstu pozitivnega vpliva na paciente. Naloga analizira tveganja v oskrbovalni verigi, od dobave osnovnih materialov do končnega uporabnika, ter predstavlja koncept inovativnih zdravil, ki so zaradi svoje narave izpostavljena dodatnim tveganjem. Glavni cilj naloge je pokazati pomen učinkovitega upravljanja tveganj za zagotavljanje neprekinjene dostave zdravil, kar posledično zmanjšuje stroške in etične izzive ter izboljšuje zdravstvene izide pacientov. The master's thesis addresses the issue of risk management and business continuity in the supply chain of innovative pharmaceuticals. The uninterrupted supply of these medicines is crucial as it directly impacts the lives and health of patients. Pharmaceutical companies face various challenges, such as global pandemics, political conflicts, macroeconomic instability, and extreme weather events, necessitating robust risk management systems. The thesis presents the process of strategic risk management in accordance with ISO 31000 and the implementation of a business continuity system in accordance with ISO 22301 in one of the leading pharmaceutical companies. It examines the key differences and improvements brought by these systems, particularly in terms of their positive impact on patients. The thesis analyzes risks within the supply chain, from the procurement of raw materials to the end user, and introduces the concept of innovative medicines, which are exposed to additional risks due to their nature. The main goal of the thesis is to demonstrate the importance of effective risk management in ensuring the uninterrupted delivery of medicines, which in turn reduces costs and ethical challenges while improving patient health outcomes. tveganje inovativno zdravilo neprekinjeno poslovanje nabavna veriga risk management inovative medicine business continuity supply chain true true false [M. Korošec] Slovenski jezik Angleški jezik Magistrsko delo/naloga 2025-03-27 17:38:11 2025-05-14 15:24:40 2025-05-15 03:10:03 0000-00-00 00:00:00 2025 0 Maribor 0 Celje 1 spletni vir (1 datoteka PDF (XII, 59 str.)) 0000-00-00 NiDoloceno NiDoloceno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 658.788:661.12(043.2) 235907587 MAG_Korosec_Matjaz_2025.pdf MAG_Korosec_Matjaz_2025.pdf 1 4CA6C633D7E1A9276D038CD206F626F1 18aa25e9b6358f62ac9aee378c2daac6516b624466259d9cf47e3bd45bb3e683 d4bbf444-1a9c-11f0-ba2f-00155d000105 https://dk.um.si/Dokument.php?lang=slv&id=190336 Fakulteta za logistiko 0 0 0